We aimed to evaluate the influence of genetic polymorphisms involved in deferasirox metabolism and transport on its pharmacokinetics and treatment toxicity, in a cohort of β-thalassaemic children.

Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients

ALLEGRA, SARAH
First
;
DE FRANCIA, SILVIA;CUSATO, JESSICA;MASSANO, DAVIDE;LONGO, Filomena;PIGA, Antonio Giulio
Co-last
;
D'AVOLIO, ANTONIO
Co-last
2017

Abstract

We aimed to evaluate the influence of genetic polymorphisms involved in deferasirox metabolism and transport on its pharmacokinetics and treatment toxicity, in a cohort of β-thalassaemic children.
18
6
539
554
BCRP1; CYP1A1; CYP1A2; CYP2D6; LIC; SNP; creatinine; ferritin; iron overload; β-thalassemia
Allegra, Sarah; De Francia, Silvia; Cusato, Jessica; Arduino, Arianna; Massano, Davide; Longo, Filomena; Piga, Antonio; D'Avolio, Antonio
File in questo prodotto:
File Dimensione Formato  
D'Avolio - Deferasirox pharmacogenetic influence on pharmacokinetic efficacy.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 4.22 MB
Formato Adobe PDF
4.22 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1635828
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact